Fennec Pharmaceuticals (FRX) Price & Analysis

Compare

32 Followers

FRX Stock Chart & Stats

C$12.30

C$0.03(0.34%)

At close: Jan 08 4:00 PM EST

C$12.30

C$0.03(0.34%)

Day’s Range― - ―

52-Week RangeC$7.02 - C$13.83

Previous CloseN/A

Volume1.30K

Average Volume (3M)686.00

Market Cap

C$415.82M

Enterprise ValueC$241.63M

Total Cash (Recent Filing)C$21.93M

Total Debt (Recent Filing)C$18.09M

Price to Earnings (P/E)―

Beta1.91

Next Earnings

Apr 01, 2026

EPS Estimate

0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding34,139,973

10 Day Avg. Volume43

30 Day Avg. Volume686

Financial Highlights & Ratios

PEG Ratio3.19

Price to Book (P/B)-22.88

Price to Sales (P/S)2.83

P/FCF Ratio4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$20.56

Price Target Upside67.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet And Commercial EfficiencyElimination of outstanding debt combined with a lean commercial model improves financial flexibility and supports potential high operating margins and sustainable EBITDA growth.

Clinical DifferentiationFDA approval for PEDMARK as the only therapy shown to reduce cisplatin-related hearing loss creates a unique clinical position that can drive physician preference and formulary inclusion.

Guideline Inclusion And Market ExpansionInclusion of PEDMARK in national clinical guidelines for adolescents and young adults expands the eligible patient population, supporting broader commercial uptake beyond pediatrics.

Bears Say

Commercial Adoption RiskUncertain commercial adoption of PEDMARK could limit revenue growth if clinicians or payers are slow to prescribe or reimburse the therapy.

Intellectual Property RiskChallenges to intellectual property protection could enable competitor entries that erode pricing power and market share.

Fennec Pharmaceuticals News

Fennec presents real world date on use of Pedmark

Fennec (FENC) Pharmaceuticals announced new real world data supporting potential use of Pedmark in adults with head and...

5d ago

FENC

3 ‘Strong Buy’ Stocks to Buy Now, 2/12/2026, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

12d ago

FENC

GENI

Fennec initiated with a Buy at B. Riley

B. Riley initiated coverage of Fennec (FENC) with a Buy rating and $16 price target The firm believes...

13d ago

FENC

Fennec Showcases Real-World Data Backing PEDMARK Use in Adult Head and Neck Cancer

The latest update is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). Fennec Pharmaceuticals reported new real-world data indicating...

5d ago

FENC

Fennec initiated with an Overweight at Piper Sandler

Piper Sandler analyst David Amsellem last night initiated coverage of Fennec (FENC) with an Overweight rating and $18...

2M ago

FENC

Fennec initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Fennec (FENC) with an Overweight rating and $18 price target Published first on...

2M ago

FENC

Southpoint Trims Stake in Fennec Pharmaceuticals to 8%

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. Southpoint Capital Advisors LP has reduced its stake in...

2M ago

FENC

Fennec: Japanese PEDMARK Success and Debt Elimination Drive Upside Potential and Support Buy Rating

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Fennec Pharmaceuticals today and set a price target...

2M ago

FENC

Fennec Pharmaceuticals Supports New Trial for Hearing Loss Prevention in Cancer Treatment

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an announcement. Fennec Pharmaceuticals announced an investigator-sponsored trial by City of...

3M ago

FENC

Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK

Fennec (FENC) Pharmaceuticals announced the planned initiation of an investigator-sponsored study, IST, by City of Hope, a U.S....

3M ago

FENC

Fennec Pharmaceuticals Reports Positive Results for PEDMARK® in Japan

The latest announcement is out from Fennec Pharmaceuticals ( ($TSE:FRX) ). Fennec Pharmaceuticals announced positive results from a...

3M ago

FENC

Fennec announces Phase 2/3 STS-J01 trial met primary endpoint

Fennec (FENC) Pharmaceuticals announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK for...

3M ago

FENC

Fennec Pharmaceuticals Completes Full Debt Redemption, Strengthening Financial Position

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an update. Fennec Pharmaceuticals has successfully completed the full redemption of...

3M ago

FENC

Fennec completes full debt redemption

Fennec (FENC) Pharmaceuticals has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund...

3M ago

FENC

FRX FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?

Fennec Pharmaceuticals lowest stock price was C$7.02 and its highest was C$13.83 in the past 12 months.

What is Fennec Pharmaceuticals’s market cap?

Fennec Pharmaceuticals’s market cap is C$415.82M.

When is Fennec Pharmaceuticals’s upcoming earnings report date?

Fennec Pharmaceuticals’s upcoming earnings report date is Apr 01, 2026 which is in 35 days.

How were Fennec Pharmaceuticals’s earnings last quarter?

Fennec Pharmaceuticals released its earnings results on Nov 13, 2025. The company reported -C$0.028 earnings per share for the quarter, beating the consensus estimate of -C$0.031 by C$0.003.

Is Fennec Pharmaceuticals overvalued?

According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fennec Pharmaceuticals pay dividends?

Fennec Pharmaceuticals does not currently pay dividends.

What is Fennec Pharmaceuticals’s EPS estimate?

Fennec Pharmaceuticals’s EPS estimate is 0.06.

How many shares outstanding does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals has 34,139,973 shares outstanding.

What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?

Fennec Pharmaceuticals reported an EPS of -C$0.028 in its last earnings report, beating expectations of -C$0.031. Following the earnings report the stock price went down -1.109%.

Which hedge fund is a major shareholder of Fennec Pharmaceuticals?

Currently, no hedge funds are holding shares in TSE:FRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fennec Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-16.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals (FRX) Earnings & Revenues

Historic Earnings Reports

FRX Stock 12 Month Forecast

Average Price Target

C$20.56

▲(67.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","10":"C$10","15":"C$15","20":"C$20","25":"C$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24.67125558,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$24.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.55937965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$20.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.81812903,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$17.82</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10,15,20,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.205,11.317788890769231,12.430577781538462,13.543366672307691,14.656155563076922,15.768944453846153,16.881733344615384,17.994522235384615,19.107311126153846,20.220100016923077,21.332888907692308,22.44567779846154,23.55846668923077,{"y":24.67125558,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.205,11.001490742307693,11.797981484615384,12.594472226923077,13.39096296923077,14.187453711538462,14.983944453846155,15.780435196153846,16.57692593846154,17.373416680769232,18.16990742307692,18.966398165384618,19.762888907692307,{"y":20.55937965,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.205,10.79062531,11.37625062,11.96187593,12.54750124,13.13312655,13.718751860000001,14.30437717,14.89000248,15.47562779,16.061253100000002,16.64687841,17.23250372,{"y":17.81812903,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.08,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.805,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.21,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.205,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >